ReviewPatient preference and adherence2013
Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review.
Review in Patient preference and adherence, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03155906 (Integrated Treatment of Hepatitis C Virus Infection Among Patients With Injecting Drug Abuse), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Integrated Treatment of Hepatitis C Virus Infection Among Patients With Injecting Drug Abuse:a Randomised Controlled Trial (INTRO-HCV)
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals.BMC public health · 2016Pooled it
- Distrust in the Health Care System and Adherence to Direct-Acting Antiviral Therapy among People with HepatitisViruses · 2024Trial
- Relationship between depressive symptoms and adherence to direct-acting antivirals: Implications for Hepatitis C treatment among people who inject drugs on medications for opioid use disorder.Drug and alcohol dependence · 2022Trial
- Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV).PLoS medicine · 2021Trial
- DOES IT WORK? -a randomized controlled trial to test the efficacy of HCV and HIV-related education on drug users in MMT, China.BMC infectious diseases · 2019Trial
- Epidemiology of hepatitis C virus infection among people receiving opioid substitution therapy (ECHO): study protocol.BMC infectious diseases · 2015Trial
- Shorter Duration Hepatitis C Virus Treatment is Associated with Better Persistence to Prescription Refills in People Who Inject Drugs: A Real-World Study.Advances in therapy · 2023Article
- Pilot Outreach Program in Remedis-The Promising Step toward HCV Elimination among People Who Inject Drugs.International journal of environmental research and public health · 2022Article
- Experiences of Hope after Treatment of Hepatitis C Infection-A Qualitative Study.International journal of environmental research and public health · 2022Article
- Substance Use Disorder Treatment Providers' Knowledge and Opinions Toward Testing and Treatment of Chronic Hepatitis C in Rural North Carolina.Rural mental health · 2022Article
- High HCV cure rates among people who inject drugs and have suboptimal adherence: A patient-centered approach to HCV models of care.The International journal on drug policy · 2021Article
- Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities.Harm reduction journal · 2020Article
- Reported Low Uptake of HCV Testing among People Who Inject Drugs in Urban Vietnam.BioMed research international · 2020Article
- Enhanced learning and retention of medical information in Alzheimer's disease after differential outcomes training.PloS one · 2020Article
- Peer involvement and cross-sector efforts in establishing integrated treatment of hepatitis C virus infection for people with substance use disorders: experiences from Norway.Substance abuse treatment, prevention, and policy · 2019Article
- Hepatitis C Virus Treatment Status and Barriers among Patients in Methadone Maintenance Treatment Clinics in Guangdong Province, China: A Cross-Sectional, Observational Study.International journal of environmental research and public health · 2019Observational
- Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV).BMC infectious diseases · 2019Article
- Factors associated with health-related quality of life in a large national sample of patients receiving opioid substitution treatment in Germany: A cross-sectional study.Substance abuse treatment, prevention, and policy · 2019Article
- Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study.PloS one · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION AND
methodsHepatitis C virus (HCV) infections are highly prevalent amongst people who inject drugs (PWID). Despite well documented evidence of its effectiveness, suggested cost-effectiveness, and potential to reduce HCV prevalence rates, the uptake of antiviral HCV treatment by PWID is low. This nonsystematic literature review describes factors associated with the uptake, adherence, and efficacy of HCV treatment among PWID and discusses strategies to increase their uptake of treatment.
resultsLow HCV treatment uptake among PWID is associated with a number of patient-related and provider-related barriers. Beliefs and fears about low efficacy and adverse effects on the patient's part are common. A substantial number of factors are associated with the chaotic lifestyle and altered social functioning of PWID, which are often associated with decompensation or relapsing into drug addiction. This may lead to perceived low adherence with treatment and low efficacy on the provider's part too, where lack of support, inadequate management of addiction, and other drug-related problems and poor treatment of side effects have been described. Practical issues such as the accessibility of treatment and finances also play a role. Strategies to improve the HCV treatment rate among PWID involve pretreatment management and assessment, a multidisciplinary approach, management of side effects, and enhanced education and counseling.
conclusionSpecific factors are associated with poorer treatment outcomes in PWID on the side of both the patient and the treatment system. However, given that PWID can achieve treatment adherence and sustained virologic response rates comparable with those in nondrug users, drug use per se should not be considered a criterion for exclusion from treatment. Further development of measures leading to higher uptake of treatment and adherence in PWID and appropriate adaptation of HCV treatment guidelines represent important tools in this regard.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.